{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:08:00Z","timestamp":1776434880520,"version":"3.51.2"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clml.2023.10.011","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T10:43:45Z","timestamp":1700736225000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"24","author":[{"given":"Shai","family":"Shimony","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.clml.2023.10.011_bib0001","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.10.011_bib0002","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41375-021-01213-5","volume":"35","author":"Wieduwilt","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.10.011_bib0003","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.10.011_bib0004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.24285","article-title":"Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission","volume":"91","author":"Seftel","year":"2016","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.clml.2023.10.011_bib0005","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.10.011_bib0006","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2023.10.011_bib0007","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3324\/haematol.2020.251686","article-title":"Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"106","author":"Geyer","year":"2021","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.clml.2023.10.011_bib0008","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2020007311","article-title":"Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia","volume":"137","author":"Ribera","year":"2021","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2023.10.011_bib0009","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2023.10.011_bib0010","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","article-title":"Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial","volume":"7","author":"Bassan","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2023.10.011_bib0011","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2020002439","article-title":"Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia","volume":"5","author":"Advani","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2023.10.011_bib0012","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/10428194.2019.1680839","article-title":"Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"61","author":"Derman","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.clml.2023.10.011_bib0013","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jha2.224","article-title":"Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults","volume":"2","author":"Patel","year":"2021","journal-title":"EJHaem"},{"issue":"18","key":"10.1016\/j.clml.2023.10.011_bib0014","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1182\/bloodadvances.2023009976","article-title":"Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2023.10.011_bib0015","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1080\/0284186X.2023.2258450","article-title":"Impact of body mass index on outcome and treatment-related toxicity in young adults with acute lymphoblastic leukemia","volume":"62","author":"Egnell","year":"2023","journal-title":"Acta Oncol"},{"issue":"8","key":"10.1016\/j.clml.2023.10.011_bib0016","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.clml.2023.10.011_bib0017","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/cncr.30037","article-title":"Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia","volume":"122","author":"Fathi","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2023.10.011_bib0018","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.10.011_bib0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2015.11.012","article-title":"Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group","volume":"41","author":"Ribera","year":"2016","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.clml.2023.10.011_bib0020","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2023.10.011_bib0021","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.10.011_bib0022","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1080\/10428194.2018.1538505","article-title":"Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL","volume":"60","author":"Kim","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.clml.2023.10.011_bib0023","doi-asserted-by":"crossref","first-page":"e907","DOI":"10.1016\/j.clml.2022.06.006","article-title":"Effect of age and socioeconomic factors in the utilization of chemotherapy in acute lymphoblastic leukemia (ALL): a SEER database study of 16,196 Patients","volume":"22","author":"Joshi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2023.10.011_bib0024","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2023.10.011_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-020-00345-8","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden","volume":"10","author":"DeAngelo","year":"2020","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2023.10.011_bib0026","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3324\/haematol.2021.280433","article-title":"Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin","volume":"107","author":"Kayser","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2023.10.011_bib0027","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/cncr.31249","article-title":"Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2023.10.011_bib0028","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.10.011_bib0029","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.10.011_bib0030","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"15","key":"10.1016\/j.clml.2023.10.011_bib0031","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cncr.32139","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.011_bib0032","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/blood-2022-166035","article-title":"Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL): results of the EWALL-INO study","volume":"140","author":"Chevallier","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.011_bib0033","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2022-162235","article-title":"Inotuzumab ozogamicin induction followed by standard chemotherapy yields high remission rates and promising survival in older (>55 years) patients with de novo B-lymphoblastic leukemia (GMALL-Initial1 Trial)","volume":"140","author":"Stelljes","year":"2022","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.clml.2023.10.011_bib0034","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.10.011_bib0035","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2007-03-080325","article-title":"Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo","volume":"110","author":"Kang","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.10.011_bib0036","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2023.10.011_bib0037","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","article-title":"Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts","volume":"20","author":"Suryani","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.clml.2023.10.011_bib0038","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.clml.2023.10.011_bib0039","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.10.011_bib0040","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.clml.2023.10.011_bib0041","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"25","key":"10.1016\/j.clml.2023.10.011_bib0042","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.10.011_bib0043","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","article-title":"Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia","volume":"79","author":"Diaz-Flores","year":"2019","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.clml.2023.10.011_bib0044","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.011_bib0045","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/blood-2019-129988","article-title":"A multicenter phase I study combining venetoclax with mini-hyper-CVD in older adults with untreated and relapsed\/refractory acute lymphoblastic leukemia","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.10.011_bib0046","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2023.10.011_bib0047","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.clml.2023.10.011_bib0048","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2023.10.011_bib0049","volume":"140","author":"Litzow","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.011_bib0050","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2022-159397","article-title":"Blinatumomab during consolidation in high-risk philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia adult patients: a two-cohort comparison within the GRAALL-2014\/B Study","volume":"140","author":"Boissel","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2023.10.011_bib0051","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II Trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.011_bib0052","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1182\/blood-2021-146214","article-title":"Dose reduced chemo in sequence with blinatumomab for newly diagnosed older patients with B-precursor adult lymphoblastic leukemia (ALL): results of the ongoing GMALL Bold Trial","volume":"138","author":"Goekbuget","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.10.011_bib0053","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.clml.2023.10.011_bib0054","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2023.41.16_suppl.7000","article-title":"Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed\/refractory adult B-cell acute lymphoblastic leukemia (r\/r B-ALL): top line results of the pivotal FELIX study","volume":"41","author":"Roddie","year":"2023","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.clml.2023.10.011_bib0055","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10299","key":"10.1016\/j.clml.2023.10.011_bib0056","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2023.10.011_bib0057","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"17","key":"10.1016\/j.clml.2023.10.011_bib0058","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood.2021015036","article-title":"Epigenetic regulator genes direct lineage switching in MLL\/AF4 leukemia","volume":"140","author":"Tirtakusuma","year":"2022","journal-title":"Blood"},{"issue":"7954","key":"10.1016\/j.clml.2023.10.011_bib0059","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.clml.2023.10.011_bib0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/bloodadvances.2022007496","article-title":"Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma","volume":"7","author":"Barnell","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.clml.2023.10.011_bib0061","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/bloodadvances.2019000925","article-title":"Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes","volume":"3","author":"Saygin","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2023.10.011_bib0062","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2643-3230.BCD-22-0154","article-title":"Adult low-hypodiploid acute lymphoblastic leukemia emergences from preleukemic TP53-mutant clonal hematopoiesis","volume":"4","author":"Kim","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.clml.2023.10.011_bib0063","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3324\/haematol.2020.247973","article-title":"Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2023.10.011_bib0064","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.10.011_bib0065","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcomes of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.011_bib0066","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.26908","article-title":"High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed\/refractory acute lymphoblastic leukemia with Philadelphia-like fusions","volume":"98","author":"Aldoss","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.10.011_bib0067","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1182\/bloodadvances.2022007597","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL","volume":"6","author":"Aldoss","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.clml.2023.10.011_bib0068","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.10.011_bib0069","article-title":"Philadelphia-like genetic rearrangements in adults with B-cell ALL: refractoriness to chemotherapy and response to tyrosine kinase inhibitor in ABL class rearrangements","volume":"7","author":"Senapati","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"28","key":"10.1016\/j.clml.2023.10.011_bib0070","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.10.011_bib0071","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2023.10.011_bib0072","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/leu.2013.312","article-title":"The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience","volume":"28","author":"Jain","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2023.10.011_bib0073","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.26144","article-title":"Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine","volume":"96","author":"Morita","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.10.011_bib0074","article-title":"Nelarabine: when, where and how to use it when treating T-cell acute lymphoblastic leukemia","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2023.10.011_bib0075","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","article-title":"Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2023.10.011_bib0076","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2023.10.011_bib0077","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2023.10.011_bib0078","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1182\/bloodadvances.2022007197","article-title":"Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia","volume":"6","author":"Muffly","year":"2022","journal-title":"Blood Adv"},{"issue":"32","key":"10.1016\/j.clml.2023.10.011_bib0079","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.22.00307","article-title":"Inequities in Alliance acute leukemia clinical trial and biobank participation: defining targets for intervention","volume":"40","author":"Hantel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2023.10.011_bib0080","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1182\/bloodadvances.2021005148","article-title":"Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials","volume":"5","author":"Hantel","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.10.011_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2023.08.001","article-title":"Geographic disparity of outcome in patients with cancer over decades: the surveillance, epidemiology, and end results","author":"Sasaki","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2023.10.011_bib0082","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/OP.21.00662","article-title":"Time-related burdens of cancer care","volume":"18","author":"Gupta","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"15","key":"10.1016\/j.clml.2023.10.011_bib0083","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.10.011_bib0084","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:39:50Z","timestamp":1708994390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2152265023021596"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}